IBD Evidence

Einkenni

Líf með IBD: þreyta, verkir og ómældir þættir

Remissía á pappír og remissía eins og hún er upplifð eru mismunandi hlutir, og bilið er þar sem flest álagið býr.

Uppfært 3 mín lesning 40 tilvísanir Sönnunargildi 3/5

Gatn sjón af apóteki stöðvarinnar í Bautzen, Þýskalandi
Fiver, der Hellseher · CC BY-SA 4.0 · Wikimedia Commons

Þreyta

Þreyta er meðal þeirra einkenna sem oftast eru skráð í IBD og meðal þeirra sem sjaldan eru meðhöndluð. Hún viðvarandi í stórum hluta fólks þar sem bólgan er stjórnað, sem þýðir að hún er ekki einfaldlega merki um sjúkdómsvirkni.

Þættir sem stuðla að þessu eru blóðleysi (járnskortur er mjög algengur og hægt að leiðrétta), truflun á svefni, áhrif lyfja, langvarandi bólga, og andlegt álag vegna óútreiknanlegs sjúkdóms. Þeir sem hægt er að leiðrétta eru þess virði að skoða sérstaklega, því enginn mun taka þá upp fyrir þig í fimmtán mínútna viðtali sem einblínir á calprotectin.

Álag vegna þreytu í IBD

Andleg heilsa

Kvíði og þunglyndi í IBD eru verulega hærri en bakgrunnstíðni. Augljós skýringin — að lifa með óútreiknanlegum, stimpluðum, stundum þvagfalla-sjúkdómi er sársaukafull — er raunveruleg og líklega ekki öll sagan, miðað við bólgu- og þarma-heila leiðirnar sem fjallað er um á okkar þarma-heila sönnunarsíðu.

Það sem skiptir máli í reynd er að þetta er meðhöndlanlegt og oft misskilinn. Andleg stuðningur er hluti af IBD umönnun samkvæmt evrópskum leiðbeiningum og er ójafnt veittur.

Praktískt álag

  • Kvíði vegna aðgangs að salernum, sem takmarkar ferðalög, vinnu og félagslíf meira en læknar venjulega átta sig á.
  • Óútreiknanleiki. Að skipuleggja er erfitt þegar skyndileg uppsveifla getur komið án fyrirvara.
  • Fæðustjórnun. Einstaklinga-örvandi efni, engin staðfest listi, og mikið af mótsagnakenndum ráðleggingum — sjá fæði.
  • Atvinna. Þreyta og bráð þörf hafa slæm áhrif á stífa vinnuskipulag.
  • Ferðalög. Lyfjageymsla, matvælaöryggi og aðgangur — fjallað um á okkar ferðaheilsusíðu.

Epidemiología

Tíðni IBD er há og stöðug í Evrópu og Norður-Ameríku og hækkar skarpt í ný iðnvæddum löndum. Þessi landfræðilegi mynstur er eitt af sterkustu rökum fyrir umhverfisþætti — fæði, hreinlæti, sýklalyf og örveruflóra eru allt frambjóðendur, og enginn er staðfestur.

Algengar spurningar

Af hverju er ég úrvinda þótt ég sé í sjúkdómshléi?
Þreyta er oft viðvarandi þrátt fyrir að bólgan sé undir stjórn. Athugaðu fyrst ferritín og B12; það eru algengir þættir sem auðvelt er að leiðrétta og oft er litið framhjá.
Veldur streita köstunum mínum?
Líklegt er að streita hafi áhrif á einkenni, en gögnin um að hún valdi bólgu eru veikari en alþýðuskilningurinn gerir ráð fyrir. Þetta er ekki þér að kenna.
Mun ég þurfa aðgerð?
Umtalsverður minnihluti gerir það, og hlutfallið hefur lækkað eftir því sem áhrifarík meðferð kemur fyrr til — sjá meðferð.
Get ég ferðast?
Já, með skipulagningu í kringum lyf, tryggingar og matvælaöryggi.
Apótek á jarðhæð á Teltower Damm í Berlín-Zehlendorf, Þýskalandi
Singlespeedfahrer · CC0 · Wikimedia Commons

Tengd lesefni

Sönnunargrunnur þessa síðu Staflaður súlurit sem sýnir samsetningu 20 ritgerða sem vísað er til á þessari síðu eftir rannsóknartegund. 14352meta-analysis (14)randomised trial (3)review (5)other (2)
24 ritgerðir, 2015–2025. Þetta er blanda af bæði rannsóknum og samantektum, sem er sú staða sem kröfu um orsök er skynsamlegt að gera. Heimild: tilvísunarlisti þessarar síðu, hér að neðan.

Tilvísanir

Hver tilvísun hér að neðan tengist upprunalegu ritrýndu skjalinu á PubMed eða í gegnum DOI. Ekkert hér er staðgengill fyrir læknisfræðilega ráðgjöf.

  1. Evaluating the causal connections between sleep duration and disease prevalence: A comprehensive systematic review and meta-analysis of Mendelian randomization studies Wang Z, Yao L, Tu M · Medicine · 2026 · Meta-analysis DOIPubMed 41517697Full text
  2. Management of paediatric ulcerative colitis, part 2: Acute severe colitis-An updated evidence-based consensus guideline from the European Society of Paediatric Gastroenterology, Hepatology and Nutrition and the European Crohn's and Colitis Organization Assa A, Aloi M, Van Biervliet S, et al. · Journal of pediatric gastroenterology and nutrition · 2025 · Clinical guideline DOIPubMed 40528309
  3. Management of paediatric ulcerative colitis, part 1: Ambulatory care-An updated evidence-based consensus guideline from the European Society of Paediatric Gastroenterology, Hepatology and Nutrition and the European Crohn's and Colitis Organisation Wine E, Aloi M, Van Biervliet S, et al. · Journal of pediatric gastroenterology and nutrition · 2025 · Clinical guideline DOIPubMed 40677018Full text
  4. North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition position paper on the therapeutic drug monitoring in pediatric inflammatory bowel disease Felipez LM, Ali S, de Zoeten EF, et al. · Journal of pediatric gastroenterology and nutrition · 2025 · Clinical guideline DOIPubMed 40692184Full text
  5. Risk factors for herpes zoster infections: a systematic review and meta-analysis unveiling common trends and heterogeneity patterns Steinmann M, Lampe D, Grosser J, et al. · Infection · 2024 · Meta-analysis DOIPubMed 38236326Full text
  6. Human Leukocyte Antigen Signatures as Pathophysiological Discriminants of Microscopic Colitis Subtypes Zheng T, Roda G, Zabana Y, et al. · Journal of Crohn's & colitis · 2024 · Meta-analysis DOIPubMed 37768647
  7. Acute severe ulcerative colitis trials: the past, the present and the future Honap S, Jairath V, Sands BE, et al. · Gut · 2024 · Systematic review DOIPubMed 38834296Full text
  8. Vitamin D for the treatment of inflammatory bowel disease Wallace C, Gordon M, Sinopoulou V, et al. · The Cochrane database of systematic reviews · 2023 · Systematic review DOIPubMed 37781953Full text
  9. Global Hospitalization Trends for Crohn's Disease and Ulcerative Colitis in the 21st Century: A Systematic Review With Temporal Analyses Buie MJ, Quan J, Windsor JW, et al. · Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2023 · Meta-analysis DOIPubMed 35863682
  10. Nutrition, Nutritional Status, Micronutrients Deficiency, and Disease Course of Inflammatory Bowel Disease Valvano M, Capannolo A, Cesaro N, et al. · Nutrients · 2023 · Systematic review DOIPubMed 37686856Full text
  11. Twenty-first Century Trends in the Global Epidemiology of Pediatric-Onset Inflammatory Bowel Disease: Systematic Review Kuenzig ME, Fung SG, Marderfeld L, et al. · Gastroenterology · 2022 · Systematic review DOIPubMed 34995526
  12. Prevalence of symptoms of anxiety and depression in patients with inflammatory bowel disease: a systematic review and meta-analysis Barberio B, Zamani M, Black CJ, et al. · The lancet. Gastroenterology & hepatology · 2021 · Meta-analysis DOIPubMed 33721557
  13. STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD Turner D, Ricciuto A, Lewis A, et al. · Gastroenterology · 2021 · Systematic review DOIPubMed 33359090
  14. ACG Clinical Guideline: Management of Irritable Bowel Syndrome Lacy BE, Pimentel M, Brenner DM, et al. · The American journal of gastroenterology · 2021 · Clinical guideline DOIPubMed 33315591
  15. Pediatric Psoriasis Comorbidities Kittler NW, Cordoro KM · Skin therapy letter · 2020 · Clinical guideline PubMed 33196156
  16. Telemedicine and Mobile Health Technology Are Effective in the Management of Digestive Diseases: A Systematic Review Helsel BC, Williams JE, Lawson K, et al. · Digestive diseases and sciences · 2018 · Systematic review DOIPubMed 29663265
  17. Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) and the Association of Crohn's Disease and Ulcerative Colitis Patients (ACCU) in the management of psychological problems in Inflammatory Bowel Disease patients Barreiro-de Acosta M, Marín-Jiménez I, Panadero A, et al. · Gastroenterologia y hepatologia · 2018 · Systematic review DOIPubMed 29275001
  18. Quality of Life in Inflammatory Bowel Disease: A Systematic Review and Meta-analyses-Part I Knowles SR, Graff LA, Wilding H, et al. · Inflammatory bowel diseases · 2018 · Meta-analysis DOIPubMed 29562277
  19. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies Ng SC, Shi HY, Hamidi N, et al. · Lancet (London, England) · 2017 · Systematic review DOIPubMed 29050646
  20. Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target Peyrin-Biroulet L, Sandborn W, Sands BE, et al. · The American journal of gastroenterology · 2015 · Systematic review DOIPubMed 26303131
  21. Consumption of vegetables and fruit and the risk of inflammatory bowel disease: a meta-analysis Li F, Liu X, Wang W, et al. · European journal of gastroenterology & hepatology · 2015 · Meta-analysis DOIPubMed 25831134
  22. How IBD patients cope with IBD: a systematic review McCombie AM, Mulder RT, Gearry RB · Journal of Crohn's & colitis · 2013 · Systematic review DOIPubMed 22718016
  23. Iron replacement therapy in inflammatory bowel disease patients with iron deficiency anemia: a systematic review and meta-analysis Lee TW, Kolber MR, Fedorak RN, et al. · Journal of Crohn's & colitis · 2012 · Meta-analysis DOIPubMed 22405161
  24. Health-related quality of life in youth with chronic gastrointestinal disease following a biofeedback enhanced cognitive behavioral therapy intervention: A randomized controlled trial Younginer ST, Westbrook A, Buzenski J, et al. · Journal of pediatric gastroenterology and nutrition · 2026 · Randomised controlled trial DOIPubMed 41486461Full text
  25. Feasibility, Acceptability, and Preliminary Effects of a Nurse-Delivered Self-Management Program for Individuals with Inflammatory Bowel Disease: A Pilot Randomized Controlled Trial Kamp K, Yoo L, Kale T, et al. · Digestive diseases and sciences · 2026 · Randomised controlled trial DOIPubMed 42470576Full text
  26. Digital self-management programme for pain, fatigue and faecal incontinence in inflammatory bowel disease: cost-effectiveness analysis of the IBD-BOOST randomised controlled trial Roukas C, Miller L, Büttner FC, et al. · BMJ open gastroenterology · 2026 · Randomised controlled trial DOIPubMed 42386349Full text
  27. Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study Ferrante M, D'Haens G, Jairath V, et al. · Lancet (London, England) · 2024 · Randomised controlled trial DOIPubMed 39581202
  28. Early and Sustained Symptom Control with Mirikizumab in Patients with Ulcerative Colitis in the Phase 3 LUCENT Programme Danese S, Dignass A, Matsuoka K, et al. · Journal of Crohn's & colitis · 2024 · Randomised controlled trial DOIPubMed 38869019Full text
  29. Acceptance and Commitment Therapy for Adults Living With Inflammatory Bowel Disease and Distress: A Randomized Controlled Trial Naude C, Skvarc D, Maunick B, et al. · The American journal of gastroenterology · 2024 · Randomised controlled trial DOIPubMed 39162706Full text
  30. Effect of 5-Hydroxytryptophan on Fatigue in Quiescent Inflammatory Bowel Disease: A Randomized Controlled Trial Truyens M, Lobatón T, Ferrante M, et al. · Gastroenterology · 2022 · Randomised controlled trial DOIPubMed 35940251
  31. Effects of Low FODMAP Diet on Symptoms, Fecal Microbiome, and Markers of Inflammation in Patients With Quiescent Inflammatory Bowel Disease in a Randomized Trial Cox SR, Lindsay JO, Fromentin S, et al. · Gastroenterology · 2020 · Randomised controlled trial DOIPubMed 31586453
  32. Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis Sands BE, Peyrin-Biroulet L, Loftus EV Jr, et al. · The New England journal of medicine · 2019 · Randomised controlled trial DOIPubMed 31553834
  33. Epidemiology of Inflammatory Bowel Disease across the Ages in the Era of Advanced Therapies Caron B, Honap S, Peyrin-Biroulet L · Journal of Crohn's & colitis · 2024 · Review DOIPubMed 39475082Full text
  34. Hidradenitis suppurativa: an update on epidemiology, phenotypes, diagnosis, pathogenesis, comorbidities and quality of life Nguyen TV, Damiani G, Orenstein LAV, et al. · Journal of the European Academy of Dermatology and Venereology : JEADV · 2021 · Review DOIPubMed 32460374
  35. Iron Deficiency Anemia in Inflammatory Bowel Diseases-A Narrative Review Mahadea D, Adamczewska E, Ratajczak AE, et al. · Nutrients · 2021 · Review DOIPubMed 34836263Full text
  36. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities Elmets CA, Leonardi CL, Davis DMR, et al. · Journal of the American Academy of Dermatology · 2019 · Review DOIPubMed 30772097
  37. Fatigue in inflammatory bowel disease Grimstad T, Norheim KB · Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke · 2016 · Review DOIPubMed 27830906
  38. Global evolution of inflammatory bowel disease across epidemiologic stages Hracs L, Windsor JW, Gorospe J, et al. · Nature · 2025 · Journal article DOIPubMed 40307548Full text
  39. Prevalence, Characteristics, Management, and Outcomes of Difficult-to-Treat Inflammatory Bowel Disease Parigi TL, Massimino L, Carini A, et al. · Journal of Crohn's & colitis · 2025 · Journal article DOIPubMed 39269323
  40. Psychological symptoms and quality of life in patients with inflammatory bowel disease in China: A multicenter study Zhang J, Liu C, An P, et al. · United European gastroenterology journal · 2024 · Journal article DOIPubMed 38315582Full text

Þessi síða var þýdd sjálfkrafa úr ensku. Tilvísanir og tölur eru óbreyttar. Lestu upprunalega ensku ef eitthvað hljómar undarlega. Lestu upprunalega ensku